CAS 1816989-16-8

Mevociclib

CAS: 1816989-16-8

Mevociclib

Pureza: ≥98%

Peso molecular: 587.11g/mol

Ref: 54-BUP21837

N-[(1S,3R)-3-[[5-Chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-methylcyclohexyl]-5-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-2-pyridinecarboxamide

Producto controlado

CAS: 1816989-16-8

Fórmula: C₃₁H₃₅ClN₈O₂

Forma y color: Neat

Peso molecular: 587.115

Ref: TR-C293035

Mevociclib

CAS: 1816989-16-8

Mevociclib is a potent inhibitor of the Bcl-2 protein, which is considered to be a key regulator of cell death. It binds to the kinase domain of the Bcl-2 protein, inhibiting its function and promoting apoptosis. Mevociclib has shown potent antitumor activity in clinical studies against patients with high-risk diseases such as cancer and cell culture experiments against carcinoma cells. This drug also inhibits transcriptional regulation by suppressing specific genes that inhibit apoptosis pathways.

Fórmula: C₃₁H₃₅ClN₈O₂

Pureza: Min. 95%

Peso molecular: 587.11 g/mol

Ref: 3D-RXC98916

Mevociclib

CAS: 1816989-16-8

Mevociclib (SY-1365) is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.

Fórmula: C₃₁H₃₅ClN₈O₂

Pureza: 98.02% - 98.02%

Forma y color: Solid

Peso molecular: 587.11

Ref: TM-T13044